glp-1 and eye disease Drugs Diabetic Disease: Ozempic, Semaglutide, and Retinopathy Risk Updated guidance from the PCDS

23431 (May 1, 2026) - both primary federal sources that buyers can verify directly at FDA.gov

Bariatric medicine specialists at the University of Missouri Health Care note the absence of rigorous scientific data supporting microdosing effectiveness

These drinks are perfect for those who dont want to mess around with fancy drink orders that include confusing swaps and substitutions

It's a reasonable supporting ingredient, not a standalone weight-loss solution

Another DPP4 inhibitor Des-fluoro-sitagliptin was also reported to decrease the accumulation of M1 macrophages in Gck +/- mice, a -cellspecific glucokinase haploinsufficient (Gck+/) diabetic model (33)